The Clorox Company (CLX)
Key Takeaways:
Company Overview
The Clorox Company is a global consumer and professional products company with a portfolio centered on cleaning, disinfecting, food, household, and personal care brands. Its core franchises include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, with a meaningful and newly expanded health-and-hygiene platform after the GOJO acquisition added Purell and related B2B capabilities. The business is heavily skewed to mature U.S. consumer markets, but it also operates in roughly 25 countries and sells in about 95 markets. Clorox relies on strong brand equity, category leadership, and broad retail distribution, while increasingly investing in e-commerce, digital capabilities, and product innovation under its IGNITE strategy. The company’s economics remain highly exposed to retailer concentration, private-label competition, commodity and freight inflation, regulatory scrutiny, and execution risk from major transformation efforts, including ERP stabilization and acquisition integration. In short, Clorox is a high-quality branded staples business, but one facing real growth constraints and meaningful operational, leverage, and execution risks.
Business Segments
Economic Moat Analysis
Clorox has a real but limited economic moat. Its strongest advantage is a portfolio of trusted brands with leading market positions, supported by broad distribution and entrenched shopper awareness. That said, most of its businesses operate in mature, highly competitive categories where private label, retailer leverage, and price promotion remain persistent threats. The newly expanded professional hygiene platform adds some incremental stickiness through installed systems and recurring consumables, but this does not transform the business into one with a wide moat. Overall, the moat is best described as narrow: meaningful enough to support resilience and cash generation, but not strong enough to eliminate material competitive and execution risk.
Clorox owns household names with strong consumer recognition and trust, which supports repeat purchase behavior and retail visibility.
A large share of sales comes from leading positions in mature categories, which helps defend shelf presence and customer loyalty.
Broad access across major retail and e-commerce channels creates meaningful route-to-market advantage, though it is not unique enough to be a wide moat.
Consumer switching costs are low in most categories, so the moat relies more on branding and habit than on structural lock-in.
In B2B hygiene and dispensing systems, installed base and recurring consumables create some stickiness, but competition and customer bargaining power remain significant.
Ongoing product and packaging innovation helps sustain relevance, but it is usually defensive rather than a source of deeply durable advantage.
Key Strengths
- Brand Equity: The company owns widely recognized brands with strong consumer trust, which supports shelf space, repeat purchases, and pricing power in ordinary conditions.
- Category Leadership: Over 80% of sales come from brands holding No. 1 or No. 2 market share positions, indicating durable relevance in several core categories.
- Distribution Reach: Products are sold through mass retail, grocery, club, dollar, hardware, drug, pet, military, e-commerce, and B2B channels, creating broad market access.
- Recurring Demand: Household essentials such as cleaning, trash bags, cat litter, filtration, and disinfecting products generate relatively steady baseline demand.
- Portfolio Breadth: Exposure across health and wellness, household, lifestyle, and international segments reduces reliance on a single end market or product line.
- Professional Expansion: The GOJO acquisition strengthens the health-and-hygiene and institutional presence, adding recurring consumable demand in B2B channels.
- Innovation Capability: Ongoing product launches and R&D in formulations, packaging, and dispensing systems help defend relevance and support category share.
- Dividend History: The company has a longstanding record of paying dividends and continuing annual increases, which may appeal to income-oriented shareholders.
Identified Weaknesses
- Growth Profile: The business operates in mature, highly penetrated categories where organic growth is structurally difficult and often depends on price, mix, or innovation.
- Customer Concentration: Walmart alone accounts for roughly a quarter of consolidated sales, creating meaningful negotiating and volume risk.
- Leverage Load: Debt has risen materially after the GOJO acquisition and Glad buyout, reducing financial flexibility and increasing interest burden.
- Execution Burden: ERP replacement, digital transformation, and organizational simplification introduce short-term disruption and the risk of delayed benefits.
- Margin Sensitivity: Earnings are highly exposed to input-cost inflation, freight, labor, and promotional intensity, with limited room for error.
- Private Label Pressure: Store brands and lower-cost alternatives can erode volume, force promotions, and weaken mix in several categories.
- International Scale: Only a minority of sales comes from international markets, limiting geographic diversification and upside leverage outside the U.S.
- Acquisition Risk: Integrating GOJO and operating Glad without former JV support increases complexity, cost, and the risk of missed synergy targets.
Growth Opportunities
- B2B Expansion: GOJO and existing professional brands give Clorox a larger foothold in healthcare, institutional, and food-service channels with recurring replenishment potential.
- Digital Commerce: Better execution in e-commerce, search, and retailer media could help protect brand visibility and capture incremental demand.
- Innovation Pipeline: New formats, premium offerings, and line extensions can support share gains and defend against commoditization.
- Operational Efficiency: The ERP and cloud transition may eventually improve supply chain visibility, inventory control, productivity, and decision quality.
- Portfolio Optimization: Management can prune weaker assets and concentrate capital on higher-return franchises and categories.
- Sustainability Positioning: Packaging reduction and sustainability claims may resonate with certain consumers and retailers if executed credibly and cost-effectively.
- International Selectivity: Focused expansion in targeted international markets could add growth, though execution risk remains high.
- Pricing and Mix: If inflation moderates, the company may be able to retain prior price actions while improving mix through premium innovations.
Risk Factors
- Macroeconomic Pressure: Weak consumer spending, inflation, and higher interest rates can push households toward smaller packs, lower-priced alternatives, or private label.
- Retailer Power: Large retailers can demand lower pricing, higher trade spending, or more shelf space for private label, compressing margins.
- Commodity Volatility: Resins, chemicals, packaging, fuel, and freight remain volatile and can move faster than Clorox’s ability to offset costs.
- Cyber Risk: The company has already suffered a cyberattack and continues to face elevated cyber and data-security exposure, especially during system transitions and integration.
- Integration Failure: GOJO integration missteps could disrupt service levels, margins, culture, and customer retention, especially in B2B channels.
- Regulatory Risk: Cleaning, food, beauty, and OTC-adjacent products face extensive scrutiny from FDA, FTC, EPA, CPSC, and foreign regulators.
- Reputation Risk: Product safety claims, sustainability controversy, social-media backlash, or recall events could damage trusted brands quickly.
- Debt and Ratings: Higher leverage increases refinancing and covenant sensitivity; any further credit deterioration could raise financing costs and collateral demands.
- Trade and Geopolitics: Tariffs, trade restrictions, USMCA uncertainty, conflicts, and shipping-route disruptions can raise costs and complicate sourcing.
- Leadership Transition: CEO succession introduces execution uncertainty at a time when the company already faces transformation and integration complexity.
Valuation Metrics
CLX is priced at P/E 16.84 and Forward P/E 12.99, implying the market expects EPS improvement versus current earnings.
The PEG is 2.21 (above 1), which is a yellow flag for growth-at-a-reasonable-price: growth is not being valued cheaply relative to its expected trajectory.
On sales, the stock trades at P/S 1.46—moderate for a durable consumer staples franchise.
On book value, P/B 2.29 suggests the business earns returns above what accounting book captures (consistent with branded/asset-light characteristics), but it is not a deep value multiple.
Cash valuation: Cash/sh = 1.18 vs Book/sh = 0.74 indicates strong balance-sheet cash per share support relative to book.
Free-cash-flow valuation: P/FCF 24.19 is relatively rich, meaning FCF yield is not especially high and investors are paying for steadier cash generation/quality.
Enterprise valuation: EV/EBITDA 13.57 and EV/Sales 2.29 are reasonable-to-moderate; no clear distress mispricing is evident from these multiples.
Earnings & Profitability
Profitability quality looks solid: ROA 5.89%, ROE 8.79%, and ROIC 8.74%—positive and consistent with a mature staples operator rather than a high-growth compounder.
Margins: Gross Margin 58.81%, Oper. Margin 24.19%, and Profit Margin 13.57% indicate strong cost structure and pricing power for a consumer brand portfolio.
Given EPS (ttm) 4.81 and EPS next Y 6.24, the forward earnings run-rate implies meaningful improvement (~30%+ over the next year based on the provided figures).
Earnings/sales momentum: EPS Y/Y TTM 7.90% but EPS Q/Q -5.89% and Sales Q/Q -3.11%—suggests near-term softness even if the market anticipates recovery over the next year.
Earnings surprise: EPS/Sales Surprise 0.61% / 0.68% indicates results are roughly in-line (not materially outperforming recently), reducing the probability that this is a surprise-driven re-rating story.
Growth Analysis
Growth expectations: EPS next Y 6.24 and EPS next 5Y 4.53% point to mid-single-digit compounding—more value/growth blend (steady) than high-growth acceleration.
Historical growth signals are mixed: EPS past 3Y = 2.06% (low), yet Sales past 3Y = 8.79% (stronger top-line). This fits a model where volume/pricing supports sales while EPS grows slower due to costs/opex/normalization.
The Sales Y/Y TTM 5.89% supports modest ongoing revenue growth.
PEG at 2.21 suggests the market’s pricing is not especially forgiving if growth stays closer to mid-single digits; upside depends on operating leverage or margin stabilization.
Financial Health
Liquidity: Quick Ratio 0.38 and Current Ratio 0.66 are below 1, which indicates reliance on ongoing cash generation and working-capital management (typical for some consumer staples, but still not a strength).
Leverage: Debt/Eq 2.06 and LT Debt/Eq 2.06 are elevated, implying meaningful balance-sheet leverage versus equity.
Despite leverage, the company shows Cash/sh = 1.18 and Book/sh = 0.74, suggesting sufficient liquidity buffers per share.
Overall, the financial structure looks more levered than a “low-risk net cash” profile; the investment case should focus on earnings durability and cashflow rather than balance-sheet conservatism.
Ownership Structure
Ownership: Insider Own 4.81 (meaningful insider alignment) and Inst Own 88.26% (strong institutional backing).
Insider activity: Insider Trans 4.81% (interpret as notable activity; without buy/sell breakdown, treat cautiously).
High institutional ownership typically supports liquidity and governance, but it can also mean the stock’s valuation reacts to consensus earnings revisions quickly.
Market Performance
Price level vs trading range: current Price 120.93 vs 52W High 81.60 and 52W Low 81.01 is internally inconsistent (likely a data/order issue). So treat 52W-based positioning cautiously.
Recent performance is weak: Perf Month -17.07%, Perf Quarter -15.98%, Perf Half Y -34.30%, Perf 1Y -38.19% and Perf 3Y -51.08%—indicating a prolonged drawdown.
Volatility is elevated/meaningful: Volatility 30.45 and ATR(14) 2.06 imply price can swing materially.
Beta 0.57 suggests lower market sensitivity than the broader market, consistent with staples defensiveness, though the stock’s drawdown still reflects company/sector headwinds or valuation compression.
Momentum & Volatility
Relative strength/risk: RSI (14) 81.60 indicates overbought in the short window, yet the provided multi-period returns are sharply negative—this mismatch suggests either a recent rebound from lows or data timing issues.
Short positioning: Short Float 7.07% and Short Ratio 1.18 indicate not extreme short crowding; squeeze risk is not dominant.
Volatility and recent negative returns together imply that entering after a bounce can still carry drawdown risk; consider using disciplined entry levels.
Investment Recommendations
value Investor:
Given Forward P/E 12.99, P/S 1.46, and leverage/liquidity constraints (Current Ratio 0.66, Debt/Eq 2.06), a value-style entry would be at a discount to today’s price. Target roughly $105–$112 to price earnings more conservatively (seeking a forward multiple closer to low-teens or a modest P/S compression).
growth Investor:
For growth/balance (mid-single-digit EPS growth expectation at EPS next 5Y 4.53%), prefer a price that reduces downside if margins disappoint. A reasonable growth entry would be around $108–$115, aligning with waiting for either continued market weakness or a clearer earnings re-acceleration.
Investment Summary
CLX shows quality margins (gross ~58.8%, operating ~24%) and improving forward earnings (Forward P/E 12.99, EPS next Y > EPS ttm). However, growth is likely mid-single-digit (PEG 2.21; EPS next 5Y 4.53%) and leverage/liquidity aren’t pristine (Debt/Eq ~2.06; current ratio ~0.66). Value investors: wait for a discount (~$105–$112). Growth investors: buy only near $108–$115 if margin stabilization/revisions materialize.